Gland Pharma Share Price (GLAND)
as on
| Source : NSE
Gland Pharma Stock Performance
as on August 18, 2025 at 2:57 PM IST
Day's Low
Day's High
₹1,953.1₹1,995.1
0.73%
Downside
1.41%
Upside
52 Week's Low
52 Week's High
₹1,277.8₹2,13135.05%
Downside
8.32%
Upside
| Market Stats | |
| Previous Close | ₹1,975.80 |
| Open | ₹1,969.00 |
| Volume | 1.22L |
| Upper Circuit | ₹2,370.90 |
| Lower Circuit | ₹1,580.70 |
| Day's Low | ₹1,953.1 |
| Day's High | ₹1,995.1 |
| 52 Week Low | ₹1,277.8 |
| 52 Week High | ₹2,131 |
| Returns % | |
| 1 Month Return | -1.22 % |
| 3 Month Return | + 33.15 % |
| 1 Year Return | + 0.75 % |
| 3 Year Return | -17.64 % |
| 5 Year Return | + 8.59 % |
Gland Pharma Stock Fundamentals & Key Indicators
Check Gland Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹32,552.57 Cr
Return on Equity (ROE)
11.62
PE Ratio (TTM)
42.26
Return on capital employed (ROCE)
15.83
Industry PE ratio
43.28
Beta (LTM)
0.8
P/B Ratio
2.69
Dividend Yield
1.13
PEG Ratio
14.52
Quarterly Earnings Growth YOY
49.89
EPS (TTM)
42.4
Sector
Pharmaceuticals
Book Value
555.4
Technical Analysis
Bullish
View Technical Analysis
Gland Pharma Stock's Interest Amongst Investors
Gland Pharma Stock Valuation
Track how Gland Pharma P/E has moved over time to understand its valuation trends.
Gland Pharma in the last 5 years
Lowest (18.84x)
May 22, 2023
Today (42.26x)
August 14, 2025
Industry (43.28x)
August 14, 2025
Highest (67.14x)
August 12, 2021
Today’s Price to Earnings Ratio: 42.26x
Gland Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Gland Pharma.
based on 12 analysts
41.67%
Buy
16.67%
Hold
41.67%
Sell
41.67% of analysts recommend a 'HOLD' rating for Gland Pharma. Average target price of ₹1865.67
Source: S&P Global Market Intelligence
Gland Pharma Share Price Target
Get share price movements and forecasts by analysts on Gland Pharma.
Gland Pharma price forecast by 12 analysts
Downside of-5.57%
High
₹2340
Target
₹1865.67
Low
₹1138
Gland Pharma target price ₹1865.67, a slight downside of -5.57% compared to current price of ₹1967.4. According to 12 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Gland Pharma revenue growth forecast
Expected growth rate Q1, FY2027:29.61%
Forecast
Actual
Including amortisation and stock based compensations
Gland Pharma EPS growth forecast
EPS estimate Q1, FY2027:75.02%
Forecast
Actual
Source: S&P Global Market Intelligence
Gland Pharma Ltd Financial Results
Get the annual and quarterly financial summary of Gland Pharma Ltd, including revenue, profit, loss and more.
Gland Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Gland Pharma.
Gland Pharma Ltd Earnings Results
Gland Pharma Ltd’s net profit jumped 49.89% since last year same period to ₹215.48Cr in the Q1 2025-2026. On a quarterly growth basis, Gland Pharma Ltd has generated 15.51% jump in its net profits since last 3-months.
Read More about Earnings ResultsGland Pharma Ltd Dividends May,2025
In the quarter ending March 2025, Gland Pharma Ltd has declared dividend of ₹18.00 per share on 20 May 2025 - translating a dividend yield of 1.92%.
Read More about Dividends
Indices Featuring Gland Pharma Stock
Check stock indices that include Gland Pharma.
Gland Pharma Stock Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Gland Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 51.83% | 0.00 | |
| Foreign Institutions | 7.39% | 7.02 | |
| Mutual Funds | 30.67% | ||
| Retail Investors | 7.93% | ||
| Others | 2.18% | 3.52 |
Gland Pharma Ltd vs Peers
Compare market cap, revenue, PE, and other key metrics of Gland Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 32,552.57 | 1.72% | 0.53 | 698 | 5,616 | |
| HOLD | 1,62,798.61 | 18.93% | 0.50 | 2,191 | 9,360 | |
| BUY | 1,22,613.28 | 31.66% | 0.66 | 1,911 | 11,516 | |
| BUY | 48,030.42 | -1.8% | 0.78 | 1,429 | 15,261 | |
| BUY | 1,26,332.74 | 20.9% | 0.51 | 5,291 | 27,547 |
Gland Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Gland Pharma.
Gland Pharma Secures USFDA Approval for Cangrelor - 12 Aug, 2025
Gland Pharma has received USFDA approval for Cangrelor Injection, granting 180 days of exclusivity. This product, bioequivalent to KENGREAL, targets significant market potential with approximately USD 122 million in U.S. sales over the past year.Gland Pharma Reports Strong Q1 Results and Price Target Increase - 06 Aug, 2025
Gland Pharma's Q1 FY26 results show a 49.9% profit increase to Rs 215.5 crore, prompting brokerages to raise ratings and target prices. The company launched 12 new molecules and reported strong growth in Europe and other markets, despite a decline in U.S. sales.Gland Pharma Reports Strong Q1 Growth and Profit - 05 Aug, 2025
Gland Pharma's Q1 FY26 results show a 50% increase in net profit to ₹215.5 crore, with revenue rising 7% to ₹1,505.6 crore. The growth is attributed to a robust core business performance and a successful turnaround at Cenexi. The company launched 12 new molecules and continues to expand its product pipeline, positioning itself for sustained growth.Gland Pharma Continues Upward Trend Amid Buzz - 17 Jul, 2025
Gland Pharma Ltd has experienced a five-day rise, currently trading at Rs 1994.3, up 1.19%. The stock has gained 14.97% in the last month, despite a 0.77% decline over the past year. Market speculation suggests potential changes in promoter ownership.
Insights on Gland Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 1.44K Cr → 1.56K Cr (in ₹), with an average increase of 3.9% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 186.54 Cr → 215.48 Cr (in ₹), with an average increase of 13.4% per quarter
- POSITIVE IMPACT
FII Holding Up
Foreign Institutions have increased holdings from 6.90% to 7.39% in Jun 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 3 months, GLAND stock has moved up by 33.2%
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 31.3% return, outperforming this stock by 30.6%
- NO EFFECT
Promoter Holding Unchanged
Promoters holdings remained unchanged at 51.83% of holdings in Jun 2025 quarter
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 132.1% return, outperforming this stock by 149.7%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 31.16% to 30.67% in Jun 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 7.99% to 7.93% in Jun 2025 quarter
About Gland Pharma Ltd
Gland Pharma's operations include the development, manufacture, and marketing of a wide range of injectable drugs and active pharmaceutical ingredients. The company's product portfolio includes antibiotics, anti-emetics, anti-diabetics, anti-epileptics, and other therapeutic categories. Its top products include cephalosporins, penicillins, and other injectable antibiotics.
Gland Pharma is well known for its popular brands, such as Cephalosporin, Penicillin, and Amikacin. These brands have been widely used in hospitals and clinics across India, as well as in other countries. In addition, the company has developed and launched a wide range of generic and branded injectables, including Cefazolin, Cefuroxime, and Amikacin.
Revenue: ₹1,505.62Cr as on June 2025 (Q1 FY26)
Net Profit: ₹215.48Cr as on June 2025 (Q1 FY26)
Listing date: 20 Nov, 2020
Chairperson Name: Yiu Kwan Stanley Lau
| Organisation | Gland Pharma Ltd |
| Industry | Pharmaceuticals |
| CEO | Yiu Kwan Stanley Lau |
| E-voting on shares | Click here to vote |
Mutual Funds that own Gland Pharma Stock
Check out the Mutual Funds with significant holdings in Gland Pharma.
FAQs
What is Gland Pharma share price today?
Gland Pharma share price today stands at ₹1967.4, Open: ₹1969, Previous Close: ₹1975.8, High: ₹1995.1, Low: ₹1953.1, 52 Week High: ₹2131, 52 Week Low: ₹1277.8 as on .
How to buy Gland Pharma shares ?
To buy Gland Pharma shares, you need to follow these steps:
- Open a Demat account and Trading account on INDmoney
- Fund your Trading account
- Search for GLAND or Gland Pharma Ltd on the INDmoney app to check live prices of the stock
- Click on Buy or SIP to place an order to invest in Gland Pharma shares. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
What is today's traded volume of Gland Pharma?
Today's traded volume of Gland Pharma is 1.22L. Which means that 1.22L shares of Gland Pharma were bought and sold on the stock market during today's trading session.
What is Gland Pharma's market cap today?
Today's market capitalisation of Gland Pharma is ₹32,552.57 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Gland Pharma?
Gland Pharma’s 52 week high is ₹2131 and 52 week low is ₹1277.8. The current share price of Gland Pharma is ₹1967.4, which is -7.68% down from its 52 week high and 53.97% up from its 52 week low.